STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision ...

STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced a leadership ...

Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2025, Neda Nikpoor, MD, of Jenkins Eye ...

LAKE FOREST, Calif., February 11, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, ...

ICL sales of $312.5 million, including China ICL sales of $161.0 million ICL sales Ex. China of $151.6 million, up 13% from prior year Gross margin at 76.3% vs. 78.4% year ago Net loss of $(20.2 ...

Greetings and welcome to the STAAR Surgical Fourth Quarter 2024 Earnings Webcast. As a reminder, this event is being recorded today Tuesday, February 11th, 2025. During today's presentation, all ...

STAAR's lens used in refractive surgery is called an Implantable Collamer® Lens or 'ICL', which includes the EVO Visian ICL™ product line. More than 1,000,000 Visian® ICLs have been implanted ...

STAAR generates worldwide revenue almost exclusively from the sales of implantable Collamer lenses (ICLs). The company markets and sells these lenses under the "EVO" family for refractive surgery ...